Royalty Report: Drugs, Assay, Drug Discovery – Collection: 332261

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 13

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 13

Primary Industries

  • Drugs
  • Assay
  • Drug Discovery
  • Disease
  • Diagnostic
  • Proteins
  • Respiratory
  • Fibrosis
  • Surgical
  • Instruments

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 332261

License Grant
Included with this collaboration agreement is information for a third party license.  The collaboration is to screen the Materials against the Assays.

In the third party license, the University grants the use of the assay.

License Property
The assay is for the mutant cystic fibrosis transmembrane regulator or CFTR.
Field of Use
Licensee has Assays which have the potential to identify therapeutic and/or diagnostic products.

IPSCIO Record ID: 347053

License Grant
Included with this collaboration agreement is information for a third party license.  The collaboration is to screen the Materials against the Assays.

In the third party license, the University of Canada grants the use of the assay.

License Property
The assay is for the multidrug resistance protein.
Field of Use
Licensee has Assays which have the potential to identify therapeutic and/or diagnostic products.

IPSCIO Record ID: 256291

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensee, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensor.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensee, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

For patentable inventions, Licensor grants to an exclusive, royalty free worldwide license to its rights in any Joint Invention and any invention made by made by any CFFT employee resulting from the Research Project to research, develop, manufacture, use, sell and import products.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

CFTR is the key protein associated with cystic fibrosis.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.

Cystic fibrosis (CF) is a life-threatening genetic disease that causes fatal lung infections and serious digestive complications. A mutation in the CFTR gene is one of the key factors that ultimately leads to the symptoms, complications and premature mortality in people with cystic fibrosis.

IPSCIO Record ID: 305717

License Grant
The Foundation awarded the Licensee to conduct a feasibility study using high throughput screening for cystic fibrosis targets. The Foundation also selected and provided support for the Company to conduct this high throughput screening with respect to the cystic fibrosis transmembrane conductance regulator (CFTR) target identified by the Foundation.

The parties have been conducting a research program aimed at identification and design of “Potentiator” and “Corrector” compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of CFTR in different ways and with different anticipated results.

In 2004, the parties executed the Existing Agreement. The Existing Agreement contemplated that during the course of the research program, the Company would select either the Potentiator or the Corrector approach as its Primary Program (to which a majority of resources under the research program would be directed) and the other approach would be designated as an Alternative Program (to which the balance of resources would be directed).

This amendment is with respect to additional funding for the Potentiator Compounds.

License Property
The Foundation conducts research for new therapies.  They expedite the early stages of a drug and bridge the discovery gap between the academic institutions and the pharmaceutical industry.

The research program is aimed at identification and design of Potentiator and Corrector compounds, both of which are directed as a principal mode of therapeutic action at modulation of the biological effect of cystic fibrosis transmembrane conductance regulator (CFTR) in different ways and with different anticipated results.

Field of Use
The field of use is for the treatment of Cystic Fibrosis which is a rare genetic disease that affects the lungs, pancreas, and other organs.

Licensee is a funding company that collaborates with innovators from academic institutions, research hospitals and not-for-profits biotechnology companies to assist with drug research.

IPSCIO Record ID: 257285

License Grant
The Parties have been collaborating on a project to develop in silico models that guide the identification of CFTR corrector or potentiator compounds for therapeutic intervention.

Under the Agreement, the Parties agreed to conduct additional research activities aimed at developing a compound to correct a malfunction of the cystic fibrosis transmembrane conductance regulator protein.

As of the Effective Date and until the grant of any Interruption License, the Commercial Party shall be Licensor, and, upon the grant of an Interruption License, if applicable, and thereafter, it shall be Licensee.

Interruption shall occur if before the First Commercial Sale of a Product all of the Licensor, its Affiliates, licensees, sublicensees, transferees and successors, cease to use Commercially Reasonable Efforts to research, develop and/or commercialize all Early Development Candidate or EDCs and Products in the Field.

The Parties agree to collaborate in the performance of research activities aimed at identifying Early Development Candidates, and identifying Back-Up Compounds.

With the Interruption License, Licensor grants with respect to the Research Project the Interruption License, which shall become effective solely upon written notice given by Licensee in the event of an Interruption an exclusive, even as to Licensor, worldwide license, with the right to sublicense, under the Licensor Research Project Technology and the Licensor Background Technology necessary to develop, manufacture, have manufactured. use, sell, offer to sell and import Products in the Field.

In the event that Licensor transfers all of or certain of its rights and obligations to develop and commercialize a Product in the Field at any time, the Third Party to which Licensor transfers all or certain rights and obligations to develop and commercialize the Product in the Field shall be subject to the obligations of the Interruption License.

License Property
The candidate will relate to electrophysiological assay expressing epithelial cell line.

CFTR shall mean a CF transmembrane conductance regulator protein which has the biological effect of transporting molecules across human cellular membranes.   This research and development has a goal to publish the 3D structure of CFTR including its coordinates.

TDN shall mean the Therapeutic Development Network established by Licensor.

Field of Use
The Field shall mean the diagnosis, treatment and/or prevention of CF and pulmonary diseases.
Cystic fibrosis (CF) is an inherited disease that causes thickened mucus to form in the lungs, pancreas and other organs. In the lungs, this mucus blocks the airways, causing lung damage and making it hard to breathe.
Pulmonary Disease or lung disease is any problem in the lungs that prevents the lungs from working properly.

IPSCIO Record ID: 332264

License Grant
Included with this collaboration agreement is a third party license.  The collaboration is to screen the Materials against the Assays.

This third party grants the use of the technology.

License Property
Licensor has patent rights which generally apply with respect to identifications from utilization of most Combinatorial Libraries.
Field of Use
The joint discovery effort isfor  acute inflammation as the initial therapeutic focus for the collaboration.

IPSCIO Record ID: 383576

License Grant
Licensors, one being a University, grant a non-exclusive license under the Licensed Patents and Technology to make, have made, use, including use in the performance of services for, by or on behalf of its customers, have used, import, market and/or sell, in the Territory, Products designed and marketed solely for use in the Field of Use.

Licensee agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by Licensors, when appropriate.

License Property
The University Licensor and the Research Institute of the Hospital for Sick Children of Toronto, Ontario, Canada, have conducted research relating to cystic fibrosis.

Technology shall mean the information, manufacturing techniques, data, designs or concepts developed by Licensors, covering the gene for cystic fibrosis and uses thereof as covered by the claims of U.S. Patents entitled Cystic Fibrosis Gene.

Field of Use
The Field of Use shall refer to the field for which Product(s) may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Product(s) to be used for the research of, diagnosis of and screening for the disease cystic fibrosis.

IPSCIO Record ID: 332263

License Grant
Included with this collaboration agreement is a third party license.  The collaboration is to screen the Materials against the Assays.

This third party grants the use of the assay.

License Property
Licensor has certain technology utilized by Licensee in all current Combinatorial Libraries.

Hexapeptide Combinatorial Libraries
Four (4) hexapeptide libraries (L, D, acetylated L'and D) are available'· All libraries have the first ·two positions fixed with the remaining four positions consisting or'equimolar mixtures. Proof of concept has been broadly demonstrated· and· potent lead peptfcies identified. Each library contains 52 million peptides.

Tetrapeptide Combi~atorial Libraries.
Three (3) tetrapeptide l'ibraries are available. Two of the tetrapeptide libraries (one nonacetylated and the other·acetylated) contain combinations of 75 different amino acids (L, D and unnatural). Both libraries have the first position fixed with the remaining three positions consisting of equimolar mixtures. Proof of concept has been demonstrated. Each of these libraries contain approximately 30 million peptides.

Field of Use
Licensee provides combinatorial libraries to the Licensor and the Licensor screens such combinatorial libraries against hybrid yeast cells for the purpose of identifying candidates for drug development.

The Parties commenced a joint discovery effort, with acute inflammation as the initial therapeutic focus for the collaboration.

IPSCIO Record ID: 328341

License Grant
Licensor grants
a. an exclusive, worldwide license in the Fields of Use to practice Licensor Technical Information to develop, identify, make, use and sell Product(s); and
b. an exclusive, worldwide license to practice Licensor Technical Information to develop, make, use, license and sell Assays that utilize or incorporate Licensor Technical Information.
License Property
Licensor developed various technologies relating to signal transduction within cells, and Licensor owns all rights, title and interest in and to such technologies, including related patents, patent applications and unpatented technology relating to mammalian cell and/or enzyme- based assays useful in identifying compounds that regulate cellular transduction pathways.

Products shall mean any compound, formulation or composition whose utility is identified using an Assay.

Assay shall mean one or more mammalian cell and/or enzyme-based assays relating to the regulation of cellular transduction pathways, including G protein-coupled and/or tyrosine kinase-coupled receptor signal transduction pathways, which incorporates or utilizes Licensor Technical Information.

The patents include
–  Method and product for regulating cell responsiveness to external signals,
–  Using tyrosine phosphorylation of map kinase and characterization of the components of the map kinase activation pathway as a drug discovery assay system,
–  Product and process for regulating signal transduction pathways, and,
–  Method and product for regulating cell responsiveness to external signals.

Field of Use
The Fields of Use shall mean all agricultural, veterinary and human therapeutic and diagnostic uses for Licensor Technical Information.

Licensee is engaged in the discovery of novel small molecule therapeutics that act on targets in human cell signaling pathways.

IPSCIO Record ID: 203256

License Grant
The University Licensor grants a non-transferable, non-exclusive license to make, have made, use, import, offer for sale and sell the Licensed Products and the Licensed Services in the United States under the Patent Rights in the Licensed Field from the effective date of this Agreement.
License Property
The licensed property is for CF Mutations in the CFTR Gene and cystic fibrosis genetic markers.

The licensed product is  any material, composition, Licensor marker, nucleic acid sequence, nucleic acid probe, nucleic acid primer, in vitro diagnostic test, and kit containing any or all of the above, or any other product, process or method, the manufacture, use or sale of which would constitute, but for the license granted to Company, an infringement of a claim.

Field of Use
The use is in the field of bio-electric-microfluidic instrumentation/biochip cartridge for cystic fibrosis molecular diagnostic market.

IPSCIO Record ID: 211922

License Grant
This Agreement is to develop, manufacture, and commercialize innovative diagnostic systems integrating proprietary Licensor assays and technologies, and proprietary Licensee technologies and systems.

Pursuant to this agreement, The Belgian Licensor will have exclusive distribution rights in the territory.   If the R&D Collaboration results in development of a sample preparation cartridge for extraction of genomic DNA that does not incorporate proprietary Licensors technology and that is generically applicable for any procedure based on analysis of human genomic DNA, then Licensee agrees not to provide such cartridge for sale by another party to be licensed and approved for use in HLA apolipoprotein E, or CF gene (for cystic fibrosis) which are current market areas for Licensor; for a time period of (18) months.

License Property
The focus of this collaboration is the development of products integrating our proprietary technologies for sample preparation, rapid amplification and detection and Licensor's proprietary methods for genetic testing and viral genotyping.

Licensee has certain proprietary technology and experience relating to diagnostic assay reagents, protocols, and detection systems.

Products shall mean systems, subsystems, consumables, and software resulting from the R&D Collaboration and incorporating proprietary Licensee technology and proprietary Licensor technology, or systems, subsystems, and consumables incorporating proprietary Licensee technology that are specifically designed and produced according to Licensor approved Product Requirements and Specifications for use with proprietary Licensor technology and assay procedures.

Field of Use
The Field shall mean human diagnostics, as evidenced by regulatory labeling indicating approval for use in human diagnostics or for investigation of putative clinical utility by a diagnostics laboratory in a clinical research setting (e.g. For Investigational Use Only or For Research Use Only); food testing; and veterinary testing.

IPSCIO Record ID: 329676

License Grant
For the license grant for Exclusive Screens Licensor grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice the Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee.

For the license grant for Non-Exclusive Screens, License grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice Non-Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee, during the term of the Research Programs, but in no event for less than nine months after Licensee receives Materials and other information from Licensor identifying and enabling Licensee to use such Non-Exclusive Screen.

License Property
Licensor has the exclusive rights to certain technology involving the transfection and expression of G-protein- coupled receptors into yeast.  Licensor exploits similarities between the yeast and human genome to identify new drug discovery targets.

The Autocrine System shall mean that part of Licensors Technology whereby any yeast cells into which human Receptors have been inserted and grow in response to compounds produced and secreted by the same yeast cells.

Compound shall mean any Lead Compound or any Analog of any Lead Compound.

Receptor shall mean any human, G-protein-coupled, seven transmembrane receptor (including, without limitation, genes, vectors and cDNAs), and shall include any Licensee Receptor or Other Receptor.

Licensee Receptor shall mean a Receptor which is proprietary to Licensee and is provided by Licensee to Licensor for use in the Research Programs, or a Receptor which is proprietary to Licensee and is cloned or obtained by Licensor pursuant to research performed under the Research Programs, or a Receptor provided by Licensee to Licensor for use in the Research Programs which is deemed to be a Licensee Receptor.

Technology shall mean all inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, Patents and Know-How owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses, and relating to or derived from Licensors yeast-based, human G-protein-coupled receptor technology, or the Research Programs.

The Patents are titled
Expression of G Protein Coupled Receptors in Yeast, Yeast-Based Peptide Libraries for identification of G Protein-Coupled Receptor Agonists and Antagonists, and, Functional Expression of Mammalian Adenylyl cyclase in Yeast.

Field of Use
The field of use is screening assays.

Licensee recognizes that the technology represents a valuable source of development of screening assays for the discovery of potential products for manufacture, use and sale in the Territory.

IPSCIO Record ID: 298928

License Grant
The original agreement established a cooperative research relationship based on screening of their respective compound libraries using their respective assays and other jointly developed assays, and intend continue their cooperative research relationship.  With this amendment, the Parties will develop and market novel therapeutic products based on compounds identified during such research as having viral regulatory properties.

Licensor grants, during the Research Term, an exclusive, non-transferable license to use the Program Assays to screen the Program Substances in accordance with the Research Program and a nontransferable, non-exclusive license under the Licensor-owned Program Patents and the Licensor Technology other than the Program Assays to the extent necessary to screen the Program Substances against the Program Assays in accordance with the terms of the Research Program.

For the Preliminary Development by Licensee of Option-Compounds, Licensor grants to an exclusive license under the Licensor-owned and jointly owned Program Patents, the Licensor-owned and jointly owned Program Know-How and the LicensorTechnology for the limited purpose of conducting biological studies, medicinal chemistry, pharmacological development, preliminary animal safety studies or other pre-IND development activities with respect to any Option Compound within any Option Program.

License Property
Products. shall mean, collectively, the Option Products and the Program Products.

Program Product shall mean any pharmaceutical product which results during the Research Term from research conducted with respect to a Program Compound. Each Program Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.

Option Compound shall mean a Program Substance which as a result of screening activities under the Research Program, reveals Anti-Viral Activity in only one or more Option Targets,  which is not designated by Licensee as a Restricted Compound and as to which Licensor has commenced and is proceeding with preliminary development activities within two (2) years after the expiration of the Research Term.
—  Option Product shall mean any pharmaceutical product which results during the Research Term or within two (2) years thereafter, from research conducted with respect to an Option Compound. Each Option Product shall be deemed to include all indications, formulations, line extensions or modes of administration thereof.
—  Option Program shall mean either the  Herpes Simplex Virus Option Program or the Cytomegalovirus Option Program, as the case may be.

Field of Use
The Field shall mean all uses in the prevention or treatment of human or animal viral diseases and other diseases which may be designated from time to time by mutual agreement of the parties.

The Targets and Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Core Target Assays are
• Human Immunodeficiency Virus Integrase
• Human Immunodeficiency Virus Tat
• Hepatitis C Virus Helicase
The Option Targets are
• Cytomegalovirus E2
• Herpes Simplex Virus HelicasePrimase
The Option Target Assays are
• Recombinant Cytomegalovirus
• Cytomegalovirus E2
• Recombinant Herpes Simplex Virus
• Herpes Simplex Virus HelicasePrimase

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.